Valeant Pharmaceuticals: Ackman Ups Stake, ValueAct Digs In – ValueWalk Premium
Michael Pearson Valeant VRX Bill Ackman Pershing Square activism

Valeant Pharmaceuticals: Ackman Ups Stake, ValueAct Digs In

Valeant Pharmaceuticals still has plenty of supporters despite the media storm surrounding the company and its businesses practices.

Last night it emerged that Bill Ackman, one of Valeant's most staunch supporters, has upped Pershing Square’s stake in Valeant to 9.9% of the company’s outstanding shares -- a near 70% increase in Pershing's holding before recent declines.

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds. 📈

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

Sign up now. 👇

CLICK HERE TO TRY IT OUT

 

0